Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study - PubMed
3 hours ago
- #DUET Study
- #Idiopathic Hypersomnia
- #Low-Sodium Oxybate
- The DUET study evaluated the effectiveness and safety of low-sodium oxybate (LXB; Xywav®) in participants with idiopathic hypersomnia.
- Participants showed significant improvements in Epworth Sleepiness Scale (ESS) scores and Idiopathic Hypersomnia Severity Scale (IHSS) total scores after LXB treatment.
- Most participants (94.6%) reported improvement in overall idiopathic hypersomnia disease on the Patient Global Impression of Change (PGI-C).
- Improvements were also noted in sleep quality, feeling rested upon awakening, and reduced number of awakenings measured by actigraphy.
- Daytime functioning and work productivity improved, with reductions in work time missed, impairment while working, overall work impairment, and activity impairment.
- Common treatment-emergent adverse events included nausea (19.6%), dizziness (17.4%), headache (17.4%), and vomiting (10.9%).
- The study supports the effectiveness of LXB in treating idiopathic hypersomnia with a 24-hour burden of symptoms.